Cancel
Arpeggio Bio
Arpeggio Bio Employees
15 people indexed:
-
588kny67@kuxw2k1tjy3.j1z Sign up to see email
-
jy4qyd@u1vhx82v6v7.uf6 Sign up to see email
-
0dkxq@f5uqnvx5695.khj Sign up to see email
-
47n25kd@u1k2fdk28l7.d1f Sign up to see email
-
23j2@kt1k54x57s1.y6d Sign up to see email
-
q8zs@f502qhnq60y.0l0 Sign up to see email
-
lu13t@q61flzq5q77.tsl Sign up to see email
-
67d4@nx8x7uvu5hd.w1h Sign up to see email
-
ynkz6@w0vh7480nqx.xjz Sign up to see email
-
f2tq@0t80jq2fxvy.z75 Sign up to see email
-
85l@50ksh7kkw68.ful Sign up to see email
-
625js9f@5z3j9uq22yv.u79 Sign up to see email
-
vfwnk@7qj2sshqjj7.v7u Sign up to see email
-
jskk34@k6qdfqf487w.fh7 Sign up to see email
-
607@kjvwqyqvnuy.90v Sign up to see email
Arpeggio Bio Company Information
Arpeggio Bio, formerly known as Arpeggio Biosciences, is a healthcare company located in Boulder, CO, operating within the drug discovery and delivery sub-industry. With a team size of 20, Arpeggio Bio is part of the Y-Combinator S19 batch and serves regions across the United States and Canada. The company is pioneering in the development of drugs that target ‘undruggable’ proteins such as NRF2, TEAD, and GPX4, utilizing advanced technologies like AI and high-throughput RNA-sequencing. Arpeggio Bio has secured $20 million in venture funding and an additional $17 million from a Series A funding round led by Builders VC. Their lead program is making significant strides towards a development candidate for treating IO-resistant melanoma. Arpeggio Bio’s platform has shown its efficacy in rare diseases and inflammation, evidenced by a notable Phase I success. The company has established partnerships with several key players in the industry, including J&J, FORMA, Intrinsic Medicine, and Treventis Corporation, enhancing its capabilities in drug co-development, target discovery, and understanding drug mechanisms. Recently, Arpeggio Bio was recognized as a finalist for the Rising Star of the Year Award by the Colorado BioScience Association in October 2023. Additionally, they presented two posters at AACR 2023, highlighting their work in identifying novel GPX4 inhibitors through transcriptomics. Their pipeline also includes projects targeting various cancers and rare diseases, leveraging the world’s largest database of nascent RNA sequences to link compound effects with RNA activity.
Report inaccurate information
Report inaccurate information
